BridgeMD
New treatment option for Attention-Deficit/Hyperactivity Disorder (ADHD)
Official title Cannabigerol Oil for Adolescents With ADHD (CAN-ADHD)
ClinicalTrials.gov ID: NCT07592390
What this study is testing
What is Experimental: Full-spectrum CBG oil 30 mg/mL?
Experimental: Full-spectrum CBG oil 30 mg/mL is an investigational medicine, given as an once-weekly infusion into a vein, being studied as a potential treatment for attention-deficit/hyperactivity disorder (adhd).
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study aims to evaluate the potential effects of full-spectrum cannabigerol (CBG) oil on cognitive and behavioral symptoms in adolescents diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD). ADHD is a neurodevelopmental disorder characterized by inattention, hyperactivity, and impulsivity, often associated with impairments in academic, social, and emotional functioning.
- Phase 2: a mid-size study of how well it works
- Time commitment: about 12 weeks
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance. You may not know which one you got.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 12 to 17
You may be able to join if
- Adolescents aged 12 to 17 years
- Diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD) confirmed using the SNAP-IV (Swanson, Nolan and Pelham Questionnaire, version IV)
- History of previous treatment with pharmacological or non-pharmacological interventions without significant improvement of symptoms
- Absence of severe psychiatric disorders or relevant physical comorbidities
- Ability of the participant and legal guardian to understand study procedures
You likely can't join if
- Use of cannabinoid-based substances (natural or synthetic) within 30 days prior to study initiation
- History of intolerance or adverse reactions to cannabis-derived compounds (e.g., confusion, paranoia, pruritus, excessive drowsiness, vomiting...
- Presence of any significant physical comorbidity
- Presence of severe psychiatric disorder not related to ADHD
- Moderate to severe cognitive impairment
- Inability or unwillingness to complete study procedures or questionnaires adequately
See the full eligibility criteria
- Adolescents aged 12 to 17 years
- Diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD) confirmed using the SNAP-IV (Swanson, Nolan and Pelham Questionnaire, version IV)
- History of previous treatment with pharmacological or non-pharmacological interventions without significant improvement of symptoms
- Absence of severe psychiatric disorders or relevant physical comorbidities
- Ability of the participant and legal guardian to understand study procedures
- Provision of written informed consent by the legal guardian and assent by the adolescent
- Use of cannabinoid-based substances (natural or synthetic) within 30 days prior to study initiation
- History of intolerance or adverse reactions to cannabis-derived compounds (e.g., confusion, paranoia, pruritus, excessive drowsiness, vomiting, diarrhea, or seizures)
- Presence of any significant physical comorbidity
- Presence of severe psychiatric disorder not related to ADHD
- Moderate to severe cognitive impairment
- Inability or unwillingness to complete study procedures or questionnaires adequately
The study team makes the final eligibility decision.
Where it's taking place
- Tubarão, Santa Catarina, Brazil
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The study runs about 12 weeks per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 12 years to 17 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Tubarão, Santa Catarina, Brazil. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.